<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558127</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-CFT-2014-68</org_study_id>
    <secondary_id>ESR-15-10784</secondary_id>
    <nct_id>NCT02558127</nct_id>
  </id_info>
  <brief_title>Asthma With Hypersecretion-associated Gene for Cystic Fibrosis</brief_title>
  <acronym>CF-asthma</acronym>
  <official_title>Asthma With Hypersecretion-associated Gene for Cystic Fibrosis Clinical, Inflammatory and Genetics Characterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of asthma and being a carrier of genetic variants (mutations and / or
      polymorphisms) in the CFTR gene variant would cause bronchial asthma with mucus
      hypersecretion. This phenotype is characterized by a more severe disease, in terms of
      control, quality of life, exacerbations and lung function, and a different asthma the
      bronchial hypersecretion without inflammatory phenotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:

      Determine the presence of genetic variants (mutations and / or polymorphisms) of the CFTR
      gene in patients with asthma with or without bronchial mucus hypersecretion.

      Secondary objectives:

      To identify genetic variants (mutations and / or polymorphisms) of the most common CFTR gene
      in the asthmatic population. -To define the inflammatory phenotype of asthma with bronchial
      mucus hypersecretion. -To compare the severity, control, quality of life and frequency of
      exacerbations of asthma patients with or without bronchial mucus hypersecretion
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of asthmatic patients CF carriers</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noncarriers number of asthmatics</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>50 asthma patients</arm_group_label>
    <description>50 asthma patients with bronchial mucus hypersecretion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>asthma patients</arm_group_label>
    <description>50 asthma patients without bronchial mucus hypersecretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Asthma patients</intervention_name>
    <description>Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.</description>
    <arm_group_label>50 asthma patients</arm_group_label>
    <arm_group_label>asthma patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      From peripheral blood samples, the DNA extraction following the protocol saline method. From
      the DNA samples obtained CFTR gene analysis to detect genetic variants by sequencing or mass
      Next Generation Sequencing (NGS) in Miseq team Illumina platform (available in the Hospital
      de la Santa Creu i Sant be held Pau).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 100 asthmatic patients of both sexes, aged between 18 and 80 years will be
        included in the study. They have not a respiratory infection in the last month. Of the 100
        patients, 50 will be hypersecretory asthmatic patients and 50 non- hypersecretory asthmatic
        patients. Both groups have an even distribution regarding sex, age, level and disease
        control. Asthma patients were defined according to the criteria of the GEMA 2015 -GINA 2014
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria: Asthmatic patients aged between 18 and 80 years.They have not a
        respiratory infection in the last month.

        Criteria for exclusion: Presence of other lung disease, Sequelae of tuberculosis,
        Bronchiectasis (large, secondary to a different asthma respiratory disease), Cystic
        fibrosis, Residual pleural disease, Interstitial diseases, Severe comorbidity, Patients
        with oral corticosteroids or other immunomodulators by causes other than asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Crespo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau. Carrer Mas Casanovas 90.</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Goodwin J, Spitale N, Yaghi A, Dolovich M, Nair P. Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis. Can Respir J. 2012 Jan-Feb;19(1):46-8.</citation>
    <PMID>22332135</PMID>
  </results_reference>
  <results_reference>
    <citation>Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet. 1998 Jun 27;351(9120):1911-3. Erratum in: Lancet 1998 Oct 10;352(9135):1230.</citation>
    <PMID>9654257</PMID>
  </results_reference>
  <results_reference>
    <citation>Dahl M, Nordestgaard BG, Lange P, Tybjaerg-Hansen A. Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion. J Allergy Clin Immunol. 2001 May;107(5):818-23.</citation>
    <PMID>11344348</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2015</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

